Structured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
A SURMOUNT-1 analysis finds tirzepatide improves insulin sensitivity (mostly via weight loss) and beta-cell function (mostly drug-driven) in obesity without diabetes. PICO summary and commentary.
A post-hoc analysis of 307 ACCORD-BP participants with type 2 diabetes and prior stroke links intensive systolic blood pressure control to fewer cardiovascular events. PICO summary and expert commentary.
A SURMOUNT-1 analysis finds 90% of early non-responders to tirzepatide still reached 5% weight loss by week 72, supporting extending treatment. PICO summary and commentary.
A 24-week trial finds high-phenolic olive oil reduces insulin resistance in type 2 diabetes, but without changing lipids or blood pressure. PICO summary and commentary.
A crossover trial finds the Omnipod 5 Activity feature reduces insulin and blunts exercise glucose drops in type 1 diabetes, though hypoglycemia rates were unchanged. PICO summary and commentary.
A double-blind RCT finds nanocurcumin does not improve pain or neuropathy outcomes in diabetic peripheral neuropathy. PICO summary and expert commentary.
A randomized open-label pilot trial tested whether slower, flexible semaglutide titration reduces gastrointestinal dropout in type 2 diabetes versus the label regimen. PICO summary and expert commentary.
A secondary analysis of the DIAMANTE trial finds an adaptive texting intervention did not improve patient-provider communication in diabetes and depression. PICO summary and commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
